Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Heart J Qual Care Clin Outcomes ; 7(1): 59-67, 2021 01 25.
Article in English | MEDLINE | ID: mdl-32142112

ABSTRACT

AIMS: To assess low-density lipoprotein cholesterol (LDL-C) treatment target attainment among myocardial infarction (MI) patients according to the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidaemia guidelines from 2011 (LDL-C < 1.8 mmol/L or ≥50% LDL-C reduction) and 2016 (LDL-C < 1.8 mmol/L and ≥50% LDL-C reduction). METHODS AND RESULTS: Using nationwide registers, we identified 44 890 patients aged 21-74 admitted for MI, 2013-17. We included those attending follow-up visits at 6-10 weeks (n = 25 466) and 12-14 months (n = 17 117) after the event. Most patients received high-intensity statin monotherapy [84.3% (6-10 weeks) and 69.0% (12-14 months)] or statins with ezetimibe (2.7% and 10.2%). The proportion of patients attaining the 2011 LDL-C target was 63.8% (6-10 weeks) and 63.5% (12-14 months). The corresponding numbers for the 2016 LDL-C target were 31.6% (6-10 weeks) and 31.5% (12-14 months). At the 6- to 10-week follow-up, 37% of those not attaining the 2011 LDL-C target and 48% of those not attaining the 2016 target had an LDL-C level that was ≥0.5 mmol/L from the target. When comparing LDL-C measurements performed before vs. after the release of the 2016 guidelines, attainment of the 2016 LDL-C target increased from 30.2% to 35.0% (6-10 weeks) and from 27.6% to 37.6% (12-14 months). CONCLUSION: In a nationwide register, one out of three patients with a recent MI had not attained the LDL-C target of the 2011 ESC/EAS guidelines and two out of three patients had not attained the LDL-C target of the 2016 guidelines.


Subject(s)
Anticholesteremic Agents , Atherosclerosis , Cardiology , Dyslipidemias , Myocardial Infarction , Anticholesteremic Agents/therapeutic use , Cholesterol, LDL , Cohort Studies , Dyslipidemias/drug therapy , Dyslipidemias/epidemiology , Humans , Myocardial Infarction/drug therapy , Myocardial Infarction/epidemiology
2.
Eur Heart J ; 41(40): 3900-3909, 2020 10 21.
Article in English | MEDLINE | ID: mdl-32072178

ABSTRACT

AIMS: To estimate the proportion of patients with a recent myocardial infarction (MI) who would be eligible for additional lipid-lowering therapy according to the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines for the management of dyslipidaemias, and to simulate the effects of expanded lipid-lowering therapy on attainment of the low-density lipoprotein cholesterol (LDL-C) target as recommended by the guidelines. METHODS AND RESULTS: Using the nationwide SWEDEHEART register, we included 25 466 patients who had attended a follow-up visit 6-10 weeks after an MI event, 2013-17. While most patients (86.6%) were receiving high-intensity statins, 82.9% of the patients would be eligible for expanded lipid-lowering therapy, as they had not attained the target of an LDL-C level of <1.4 mmol and a ≥50% LDL-C level reduction. When maximized use of high-intensity statins followed by add-on therapy with ezetimibe was simulated using a Monte Carlo model, the LDL-C target was reached in 19.9% using high-intensity statin monotherapy and in another 28.5% with high-intensity statins and ezetimibe, while 50.7% would still be eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. When use of alirocumab or evolocumab was simulated in those who were eligible for PCSK9 inhibitors, around 90% of all patients attained the LDL-C target. CONCLUSION: Our study suggests that, even with maximized use of high-intensity statins and ezetimibe, around half of patients with MI would be eligible for treatment with PCSK9 inhibitors according to the 2019 ESC/EAS guidelines. Considering the current cost of PCSK9 inhibitors, the financial implications of the new guidelines may be substantial.


Subject(s)
Anticholesteremic Agents , Atherosclerosis , Cardiology , Dyslipidemias , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Myocardial Infarction , Percutaneous Coronary Intervention , Adolescent , Adult , Aged , Anticholesteremic Agents/therapeutic use , Dyslipidemias/drug therapy , Dyslipidemias/epidemiology , Ezetimibe/therapeutic use , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Middle Aged , Myocardial Infarction/drug therapy , PCSK9 Inhibitors , Young Adult
3.
Bull Emerg Trauma ; 3(3): 104-10, 2015 Jul.
Article in English | MEDLINE | ID: mdl-27162912

ABSTRACT

OBJECTIVE: To describe the epidemiological and clinical characteristics of fall injuries in East Azerbaijan, Iran. METHODS: This cross-sectional study was based on Hospital Information System (HIS) data for patients referred to the Imam Reza Hospital between 2008 and 2013. We recorded the demographic characteristics and epidemiological patterns of patients who were admitted to our center due to fall injuries. To standardize the reports the International Classification of Diseases (ICD), the International Classification of Diseases 9 Clinical Modification (ICD-9-CM) was used. Equally, the hospitalization period and number, admission ward, and the final status of victims after discharge from the hospital were extracted from the HIS. RESULTS: Overall we included a total number of 3397 patients with mean age of 39.2±22.7 years. There were 2501 (73.6%) men among the patients. Long bone fracture (48.1%) and intracranial injury (24.2%) were the most frequent injuries among fall injury victims. Operations on spinal cord and spinal canal structures (12.0%), Operations on nose (11.6%) were the most common operations being performed in these patients. The survival was significantly lower in patients with age more than 60 years when compared to other age groups (p=0.001). The survival rate was significantly lower in age group of >60 years, compared to other age groups (p=0.001). CONCLUSION: Given the high rate of fall injuries and death among the elderly that increases with age, appropriate measures must be taken to control and prevent injuries while prioritizing the elderly.

SELECTION OF CITATIONS
SEARCH DETAIL
...